FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207079498> ?p ?o ?g. }

• W4207079498 abstract "Despite high cure rates with standard treatment, 30% patients with Hodgkin lymphoma develop relapsed or refractory (R/R) disease. Salvage therapy followed by autologous hematopoietic cell transplantation (HCT) is considered standard of care. Brentuximab Vedotin (Bv) in combination with Bendamustine (B) has been tested in the salvage setting with promising results.We conducted a single centre retrospective chart review of patients who received BBv salvage therapy to determine its activity and safety in patients with R/R classical Hodgkin lymphoma (HL). Between May 2011- December 2019, 179 patients were diagnosed with R/R HL.Thirty patients received BBv [median age: 30 (15-59) years, females (n=15)]. Primary refractory disease in 19 patients (63%), and 26 patients (87%) had advanced stage at treatment. Most patients received BBv after 2 prior lines of therapy [n=16 (53%)]. The median number of cycles of BBv were 3 (1-6). The number of BBv cycles delivered as outpatient was 63%. The most common Grade III/IV hematological adverse event was neutropenia [n=21, (70%)], while grade III/IV non-hematological toxicities included infections in 4 (13%), neuropathy in 4(13%), skin rash in 2 (7%), GI toxicities in 3 (10%) and liver dysfunction in 2 (7%) patients. The ORR and CR rates were 79% and 62%, respectively. Seventeen patients (57%) underwent an autologous HCT and 8 (26%) underwent an Allogeneic HCT (all haploidentical). The median follow up time from BBv administration was 12 months. Six patients died: 2 = disease progression, and 4 = non-relapse causes (Infection and sepsis = 2, GVHD=2). In addition to this, one patient progressed soon after HCT and another patient relapsed 22 months post HCT. Three year Overall survival (OS) and Event free survival (EFS) probability post-BBv treatment was 75% and 58%, respectively. OS and EFS analysis based on response (viz., CMR) to BBv demonstrated that patients in CMR had better survival probability [93% (p=0.0022) 3yr-OS and 72% (p=0.038) 3yr-EFS probability].BBv is an active and well-tolerated salvage treatment for patients with R/R HL, even in refractory and advanced settings. In middle-income settings, cost constraints and access determine patient uptake of this regimen." @default.
• W4207079498 created "2022-01-26" @default.
• W4207079498 creator A5000555731 @default.
• W4207079498 creator A5002653430 @default.
• W4207079498 creator A5008847838 @default.
• W4207079498 creator A5014274620 @default.
• W4207079498 creator A5037861726 @default.
• W4207079498 creator A5039249676 @default.
• W4207079498 creator A5044733412 @default.
• W4207079498 creator A5058372714 @default.
• W4207079498 creator A5063789179 @default.
• W4207079498 creator A5067147178 @default.
• W4207079498 creator A5067254023 @default.
• W4207079498 creator A5067649736 @default.
• W4207079498 creator A5068225545 @default.
• W4207079498 creator A5070631722 @default.
• W4207079498 creator A5074194089 @default.
• W4207079498 creator A5085170131 @default.
• W4207079498 creator A5091640477 @default.
• W4207079498 date "2022-01-21" @default.
• W4207079498 modified "2023-09-27" @default.
• W4207079498 title "Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review" @default.
• W4207079498 cites W1978849352 @default.
• W4207079498 cites W1985984158 @default.
• W4207079498 cites W2044095726 @default.
• W4207079498 cites W2071474661 @default.
• W4207079498 cites W2093580676 @default.
• W4207079498 cites W2101922413 @default.
• W4207079498 cites W2119147717 @default.
• W4207079498 cites W2133201432 @default.
• W4207079498 cites W2153280042 @default.
• W4207079498 cites W2155256323 @default.
• W4207079498 cites W2156506990 @default.
• W4207079498 cites W2160498350 @default.
• W4207079498 cites W2168678052 @default.
• W4207079498 cites W2280280901 @default.
• W4207079498 cites W2598700764 @default.
• W4207079498 cites W2615861081 @default.
• W4207079498 cites W2761277905 @default.
• W4207079498 cites W2765454445 @default.
• W4207079498 cites W2776736524 @default.
• W4207079498 cites W2803000479 @default.
• W4207079498 cites W2887556146 @default.
• W4207079498 cites W2892881565 @default.
• W4207079498 cites W2899026268 @default.
• W4207079498 cites W2908920184 @default.
• W4207079498 cites W2946723631 @default.
• W4207079498 cites W2956662951 @default.
• W4207079498 cites W2979989897 @default.
• W4207079498 cites W2980313360 @default.
• W4207079498 cites W2993070286 @default.
• W4207079498 cites W2995923900 @default.
• W4207079498 cites W3006307623 @default.
• W4207079498 cites W3008760867 @default.
• W4207079498 cites W3033765098 @default.
• W4207079498 cites W3046586724 @default.
• W4207079498 cites W3143433495 @default.
• W4207079498 cites W3193838563 @default.
• W4207079498 cites W4230483407 @default.
• W4207079498 cites W4236235343 @default.
• W4207079498 cites W4293241248 @default.
• W4207079498 cites W773219832 @default.
• W4207079498 cites W950004053 @default.
• W4207079498 doi "https://doi.org/10.3389/fonc.2021.796270" @default.
• W4207079498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35127505" @default.
• W4207079498 hasPublicationYear "2022" @default.
• W4207079498 type Work @default.
• W4207079498 citedByCount "3" @default.
• W4207079498 countsByYear W42070794982022 @default.
• W4207079498 countsByYear W42070794982023 @default.
• W4207079498 crossrefType "journal-article" @default.
• W4207079498 hasAuthorship W4207079498A5000555731 @default.
• W4207079498 hasAuthorship W4207079498A5002653430 @default.
• W4207079498 hasAuthorship W4207079498A5008847838 @default.
• W4207079498 hasAuthorship W4207079498A5014274620 @default.
• W4207079498 hasAuthorship W4207079498A5037861726 @default.
• W4207079498 hasAuthorship W4207079498A5039249676 @default.
• W4207079498 hasAuthorship W4207079498A5044733412 @default.
• W4207079498 hasAuthorship W4207079498A5058372714 @default.
• W4207079498 hasAuthorship W4207079498A5063789179 @default.
• W4207079498 hasAuthorship W4207079498A5067147178 @default.
• W4207079498 hasAuthorship W4207079498A5067254023 @default.
• W4207079498 hasAuthorship W4207079498A5067649736 @default.
• W4207079498 hasAuthorship W4207079498A5068225545 @default.
• W4207079498 hasAuthorship W4207079498A5070631722 @default.
• W4207079498 hasAuthorship W4207079498A5074194089 @default.
• W4207079498 hasAuthorship W4207079498A5085170131 @default.
• W4207079498 hasAuthorship W4207079498A5091640477 @default.
• W4207079498 hasBestOaLocation W42070794981 @default.
• W4207079498 hasConcept C126322002 @default.
• W4207079498 hasConcept C141071460 @default.
• W4207079498 hasConcept C197934379 @default.
• W4207079498 hasConcept C2776694085 @default.
• W4207079498 hasConcept C2777063308 @default.
• W4207079498 hasConcept C2778191690 @default.
• W4207079498 hasConcept C2778570526 @default.
• W4207079498 hasConcept C2779338263 @default.
• W4207079498 hasConcept C2780653079 @default.
• W4207079498 hasConcept C2780775027 @default.
• W4207079498 hasConcept C2781442060 @default.

• next